A Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration

    Not Recruiting
  • End date
    Dec 30, 2022
  • participants needed
  • sponsor
    Apellis Pharmaceuticals, Inc.
Updated on 27 June 2021
Federico Grossi, MD, PhD
Primary Contact
Retina Vitreous Consultants (0.0 mi away) Contact
+124 other location
diabetic retinopathy
corrected visual acuity
pupillary dilation
macular degeneration
fundus autofluorescence


This is a 30-month, Phase III, multicenter, randomized, double-masked, sham-injection controlled study to assess the efficacy and safety of multiple IVT injections of APL-2 in subjects with GA secondary to AMD.

Condition Dry Macular Degeneration, age-related macular degeneration, Macular Degeneration, Geographic Atrophy
Treatment Sham Procedure, APL-2
Clinical Study IdentifierNCT03525613
SponsorApellis Pharmaceuticals, Inc.
Last Modified on27 June 2021

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note